Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism-Reference-Cited by-同舟云学术

Pharmacological and clinical properties of calcimimetics: Calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism

Published:2006-03 Issue:3 Volume:109 Page:339-365
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Nagano Nobuo

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference223 articles.

1. Amgen Inc. (2004). Sensipar™ (cinacalcet HCl) tablets: sensipar's prescribing information. Available at: http://www.sensipar.com.

2. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure;Antonsen;Kidney Int,1998

3. Kidney and calcitonin;Ardaillou;Nephron,1975

4. Risk factors for vertebral fractures in renal osteodystrophy;Atsumi;Am J Kidney Dis,1999

5. Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein;Awata;J Biol Chem,2001

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary Hyperparathyroidism;Surgical Clinics of North America;2024-08

2. Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients;Renal Replacement Therapy;2024-03-05

3. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients;Current Osteoporosis Reports;2023-02-27

4. Drug discovery related to zinc;Folia Pharmacologica Japonica;2023

5. The Calcium‐Sensing Receptor ( CaSR ) in Disease;GPCRs as Therapeutic Targets;2022-09-16